<DOC>
	<DOCNO>NCT01140880</DOCNO>
	<brief_summary>This study seek evaluate efficacy contingency management ( CM ) intervention compare yoke control condition eliminate illicit stimulant use decrease time initiate post exposure prophylaxis ( PEP ) , improve adherence PEP , complete PEP follow potential HIV-exposure event . Men sex men use cocaine amphetamine methamphetamine frequently also high risk sexual behavior drug use . The objective study evaluate whether use CM target stimulant use significantly aid men sex men use stimulant also engage high-risk sexual transmission behavior able initiate , adhere complete PEP , thereby optimize utility biomedical HIV prevention intervention reduce HIV incidence high-risk group MSM .</brief_summary>
	<brief_title>Biobehavioral Interventions HIV-negative , Stimulant Using Men Who Have Sex With Men</brief_title>
	<detailed_description>This prospective , randomize study . 170 participant meet inclusion exclusion criterion randomize CM NCYC ( non-contingent yoked-control condition ) arm . They provide 4-day starter-pack PEP medication ( tenofovir + emtricitabine , Truvada ) start event high-risk sexual exposure . The two intervention implement simultaneously : The CM NCYC intervention , remunerate ( via voucher ) participant base ( CM ) yoked-participant 's ( NCYC ) stimulant-metabolite-free urine sample 8 week ; , Post-exposure prophylaxis , provide risk reduction counseling , adherence counsel PEP medication 28 day event high-risk sexual exposure HIV . All participant follow 24 week , 24-weeks post-HIV-exposure , whichever longer .</detailed_description>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Male sex men ( MSM ) selfreport At least 18 year age HIVnegative serostatus baseline rapid oral HIV antibody test , sign symptoms consistent primary HIV infection ( PHI ) Selfreported stimulant use within previous 30 day Selfreport unprotected anal intercourse ( either receptive insertive ) HIVpositive status unknown partner within previous 3 month Selfreport previous hypersensitivity component Truvada ( tenofovir disoproxil fumarate emtricitabine ) In opinion study medical provider , contraindication PEP medication treatment ( laboratory testing , medical/drug interaction , ) Has use PEP previous 6 month A current resident Los Angeles County Does plan move away Los Angeles County next 6 month Willing able provide inform consent Willing able comply study requirement Does identify male sex men Under 18 year age HIV positive selfreport indicate result baseline rapid oral HIV antibody testing Has use stimulant previous 30 day selfreport Has unprotected anal intercourse ( either receptive insertive ) HIVpositive status unknown partner within previous 3 month Creatinine clearance &lt; 30 ml/min dialysis Selfreports previous hypersensitivity component Truvada ( tenofovir disoproxil fumarate emtricitabine ) ; In opinion study medical provider , exist contraindication administer Truvadabased postexposure prophylaxis ( laboratory testing , medical/drug interaction , ) Has use PEP previous six month Not current resident Los Angeles County Unwilling unable provide inform consent Unwilling unable comply study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Methamphetamine</keyword>
	<keyword>Amphetamine</keyword>
	<keyword>Cocaine</keyword>
	<keyword>HIV</keyword>
	<keyword>Post-exposure prophylaxis</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>